ABI
GILD icon

Adamant Biomedical Investments’s Gilead Sciences GILD Stock Holding History

Adamant Biomedical Investments’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$17M Sell
180,390
-16,000
-8% -$1.65M 4.06% 3
2014
Q3 		$20.9M Buy
+196,390
New +$19.2M 5.22% 1

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adamant Biomedical Investments's GILD Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Gilead Sciences (GILD) stake by 8.1% in Q4 2014, selling an estimated $1.65M and leaving 180,390 shares worth $17M. The position accounts for 4.06% of the portfolio, ranked #3.

Adamant Biomedical Investments first reported a position in GILD in Q3 2014 and has held it in 2 quarters since. The position peaked at $20.9M in Q3 2014. 1,439 funds tracked by Wall St. Rank hold GILD as of Q4 2014.

  • Adamant Biomedical Investments held 180,390 shares of Gilead Sciences worth $17M as of Q4 2014.
  • Adamant Biomedical Investments sold 16,000 Gilead Sciences shares in Q4 2014, an estimated $1.65M.
  • Gilead Sciences made up 4.06% of Adamant Biomedical Investments's portfolio in Q4 2014, its #3 holding.
  • Adamant Biomedical Investments first reported a position in Gilead Sciences in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Gilead Sciences position peaked at $20.9M in Q3 2014.
  • 1,439 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.